

Andrew G Renehan

List of Publications by Citations

Source: <https://exaly.com/author-pdf/6757355/andrew-g-renehan-publications-by-citations.pdf>

Version: 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

172
papers

13,794
citations

49
h-index

116
g-index

185
ext. papers

16,076
ext. citations

9
avg, IF

6.53
L-index

#	Paper	IF	Citations
172	Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. <i>Lancet, The</i> , 2008 , 371, 569-78	40	3482
171	Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. <i>Lancet, The</i> , 2004 , 363, 1346-53	40	1364
170	Global burden of cancer attributable to high body-mass index in 2012: a population-based study. <i>Lancet Oncology, The</i> , 2015 , 16, 36-46	21.7	529
169	Biological mechanisms linking obesity and cancer risk: new perspectives. <i>Annual Review of Medicine</i> , 2010 , 61, 301-16	17.4	447
168	Watch-and-wait approach versus surgical resection after chemoradiotherapy for patients with rectal cancer (the OnCoRe project): a propensity-score matched cohort analysis. <i>Lancet Oncology, The</i> , 2016 , 17, 174-183	21.7	428
167	Long-term outcomes of clinical complete responders after neoadjuvant treatment for rectal cancer in the International Watch & Wait Database (IWW): an international multicentre registry study. <i>Lancet, The</i> , 2018 , 391, 2537-2545	40	364
166	Obesity and cancer risk: the role of the insulin-IGF axis. <i>Trends in Endocrinology and Metabolism</i> , 2006 , 17, 328-36	8.8	362
165	Adiposity and cancer risk: new mechanistic insights from epidemiology. <i>Nature Reviews Cancer</i> , 2015 , 15, 484-98	31.3	343
164	Recent trends in incidence of five common cancers in 26 European countries since 1988: Analysis of the European Cancer Observatory. <i>European Journal of Cancer</i> , 2015 , 51, 1164-87	7.5	319
163	Obesity and cancer: pathophysiological and biological mechanisms. <i>Archives of Physiology and Biochemistry</i> , 2008 , 114, 71-83	2.2	315
162	Stem cells: the intestinal stem cell as a paradigm. <i>Carcinogenesis</i> , 2000 , 21, 469-76	4.6	261
161	Growth hormone, the insulin-like growth factor axis, insulin and cancer risk. <i>Nature Reviews Endocrinology</i> , 2011 , 7, 11-24	15.2	241
160	The Obesity Paradox in Cancer: a Review. <i>Current Oncology Reports</i> , 2016 , 18, 56	6.3	224
159	Body mass index, hormone replacement therapy, and endometrial cancer risk: a meta-analysis. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2010 , 19, 3119-30	4	190
158	Incident cancer burden attributable to excess body mass index in 30 European countries. <i>International Journal of Cancer</i> , 2010 , 126, 692-702	7.5	185
157	Extracapsular dissection for clinically benign parotid lumps: reduced morbidity without oncological compromise. <i>British Journal of Cancer</i> , 2003 , 89, 1610-3	8.7	166
156	What is apoptosis, and why is it important?. <i>BMJ: British Medical Journal</i> , 2001 , 322, 1536-8		162

155	Lifestyle factors and colorectal cancer risk (2): a systematic review and meta-analysis of associations with leisure-time physical activity. <i>Colorectal Disease</i> , 2009 , 11, 689-701	2.1	154
154	Diabetes and cancer (1): evaluating the temporal relationship between type 2 diabetes and cancer incidence. <i>Diabetologia</i> , 2012 , 55, 1607-18	10.3	151
153	Lifestyle factors and colorectal cancer risk (1): systematic review and meta-analysis of associations with body mass index. <i>Colorectal Disease</i> , 2009 , 11, 547-63	2.1	146
152	COSMOS-E: Guidance on conducting systematic reviews and meta-analyses of observational studies of etiology. <i>PLoS Medicine</i> , 2019 , 16, e1002742	11.6	139
151	Patterns of local disease failure and outcome after salvage surgery in patients with anal cancer. <i>British Journal of Surgery</i> , 2005 , 92, 605-14	5.3	127
150	Clinico-pathological and treatment-related factors influencing survival in parotid cancer. <i>British Journal of Cancer</i> , 1999 , 80, 1296-300	8.7	115
149	Pioglitazone and bladder cancer risk: a multipopulation pooled, cumulative exposure analysis. <i>Diabetologia</i> , 2015 , 58, 493-504	10.3	114
148	Meta-analysis and dose-response metaregression: circulating insulin-like growth factor I (IGF-I) and mortality. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2011 , 96, 2912-20	5.6	111
147	Insulin-like growth factor (IGF)-I, IGF binding protein-3, and breast cancer risk: eight years on. <i>Endocrine-Related Cancer</i> , 2006 , 13, 273-8	5.7	111
146	Effect of More vs Less Frequent Follow-up Testing on Overall and Colorectal Cancer-Specific Mortality in Patients With Stage II or III Colorectal Cancer: The COLOFOL Randomized Clinical Trial. <i>JAMA - Journal of the American Medical Association</i> , 2018 , 319, 2095-2103	27.4	102
145	Diabetes and cancer (2): evaluating the impact of diabetes on mortality in patients with cancer. <i>Diabetologia</i> , 2012 , 55, 1619-32	10.3	97
144	An analysis of the treatment of 114 patients with recurrent pleomorphic adenomas of the parotid gland. <i>American Journal of Surgery</i> , 1996 , 172, 710-4	2.7	92
143	Colorectal cancer incidence trends in the United States and United Kingdom: evidence of right- to left-sided biological gradients with implications for screening. <i>Cancer Research</i> , 2010 , 70, 5419-29	10.1	84
142	Acromegaly and colorectal cancer: a comprehensive review of epidemiology, biological mechanisms, and clinical implications. <i>Hormone and Metabolic Research</i> , 2003 , 35, 712-25	3.1	83
141	Elevated serum insulin-like growth factor (IGF)-II and IGF binding protein-2 in patients with colorectal cancer. <i>British Journal of Cancer</i> , 2000 , 83, 1344-50	8.7	83
140	Interpreting the epidemiological evidence linking obesity and cancer: A framework for population-attributable risk estimations in Europe. <i>European Journal of Cancer</i> , 2010 , 46, 2581-92	7.5	75
139	Body mass index does not influence post-treatment survival in early stage endometrial cancer: results from the MRC ASTEC trial. <i>European Journal of Cancer</i> , 2012 , 48, 853-64	7.5	71
138	Linking diabetes and cancer: a consensus on complexity. <i>Lancet, The</i> , 2010 , 375, 2201-2	4.0	70

137	A phase II study evaluating the use of concurrent mitomycin C and capecitabine in patients with advanced unresectable pseudomyxoma peritonei. <i>British Journal of Cancer</i> , 2008 , 99, 591-6	8.7	70
136	Body mass index at different adult ages, weight change, and colorectal cancer risk in the National Institutes of Health-AARP Cohort. <i>American Journal of Epidemiology</i> , 2012 , 176, 1130-40	3.8	69
135	Collider Bias Is Only a Partial Explanation for the Obesity Paradox. <i>Epidemiology</i> , 2016 , 27, 525-30	3.1	69
134	Factors affecting local regrowth after watch and wait for patients with a clinical complete response following chemoradiotherapy in rectal cancer (InterCoRe consortium): an individual participant data meta-analysis. <i>The Lancet Gastroenterology and Hepatology</i> , 2018 , 3, 825-836	18.8	69
133	Acromegaly, growth hormone and cancer risk. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2008 , 22, 639-57	6.5	68
132	Measuring the biological effect of presurgical metformin treatment in endometrial cancer. <i>British Journal of Cancer</i> , 2016 , 114, 281-9	8.7	64
131	Classification of and cytoreductive surgery for low-grade appendiceal mucinous neoplasms. <i>British Journal of Surgery</i> , 2012 , 99, 987-92	5.3	63
130	High-sensitivity human papilloma virus genotyping reveals near universal positivity in anal squamous cell carcinoma: different implications for vaccine prevention and prognosis. <i>European Journal of Cancer</i> , 2015 , 51, 776-85	7.5	62
129	High-risk colorectal adenomas and serum insulin-like growth factors. <i>British Journal of Surgery</i> , 2001 , 88, 107-13	5.3	62
128	Slowing down of adult body mass index trend increases in England: a latent class analysis of cross-sectional surveys (1992-2010). <i>International Journal of Obesity</i> , 2014 , 38, 818-24	5.5	57
127	The impact of obesity and bariatric surgery on circulating and tissue biomarkers of endometrial cancer risk. <i>International Journal of Cancer</i> , 2019 , 144, 641-650	7.5	56
126	Framework to construct and interpret latent class trajectory modelling. <i>BMJ Open</i> , 2018 , 8, e020683	3	52
125	Bariatric surgery, weight reduction, and cancer prevention. <i>Lancet Oncology</i> , 2009 , 10, 640-1	21.7	52
124	Mechanisms of improved survival from intensive followup in colorectal cancer: a hypothesis. <i>British Journal of Cancer</i> , 2005 , 92, 430-3	8.7	50
123	Excess adiposity and survival in patients with colorectal cancer: a systematic review. <i>Obesity Reviews</i> , 2014 , 15, 434-51	10.6	49
122	Early cellular events in colorectal carcinogenesis. <i>Colorectal Disease</i> , 2002 , 4, 76-89	2.1	49
121	Circulating Insulin-Like Growth Factor II and Colorectal Adenomas. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2000 , 85, 3402-3408	5.6	49
120	Lifestyle changes and reduction of colon cancer incidence in Europe: A scenario study of physical activity promotion and weight reduction. <i>European Journal of Cancer</i> , 2010 , 46, 2605-16	7.5	46

119	Meta-analysis in medical research: potentials and limitations. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2008 , 26, 320-9	2.8	46
118	Comparison of associations of body mass index, abdominal adiposity, and risk of colorectal cancer in a large prospective cohort study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2013 , 22, 1383-94	4	41
117	Diabetes and cancer: 5 years into the recent controversy. <i>European Journal of Cancer</i> , 2014 , 50, 2119-25	7.5	38
116	Circulating Tumor Cell Enumeration in a Phase II Trial of a Four-Drug Regimen in Advanced Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2015 , 14, 115-22.e1-2	3.8	36
115	How to Manage the Obese Patient With Cancer. <i>Journal of Clinical Oncology</i> , 2016 , 34, 4284-4294	2.2	35
114	A core outcome set for clinical trials of chemoradiotherapy interventions for anal cancer (CORMAC): a patient and health-care professional consensus. <i>The Lancet Gastroenterology and Hepatology</i> , 2018 , 3, 865-873	18.8	35
113	IGF-I, IGF binding protein-3 and breast cancer risk: comparison of 3 meta-analyses. <i>International Journal of Cancer</i> , 2005 , 115, 1006-7; author reply 1008	7.5	34
112	Ki-67 in endometrial cancer: scoring optimization and prognostic relevance for window studies. <i>Modern Pathology</i> , 2017 , 30, 459-468	9.8	33
111	Physical activity before and after diagnosis of colorectal cancer: disease risk, clinical outcomes, response pathways and biomarkers. <i>Sports Medicine</i> , 2007 , 37, 947-60	10.6	33
110	Preventing cancer, cardiovascular disease, and diabetes. <i>Lancet, The</i> , 2005 , 365, 1449-51	40	33
109	Conditional recurrence-free survival of clinical complete responders managed by watch and wait after neoadjuvant chemoradiotherapy for rectal cancer in the International Watch & Wait Database: a retrospective, international, multicentre registry study. <i>Lancet Oncology, The</i> , 2021 , 22, 43-50	21.7	31
108	Growth hormone receptor polymorphism and growth hormone therapy response in children: a Bayesian meta-analysis. <i>American Journal of Epidemiology</i> , 2012 , 175, 867-77	3.8	29
107	A specific cadherin phenotype may characterise the disseminating yet non-metastatic behaviour of pseudomyxoma peritonei. <i>British Journal of Cancer</i> , 2006 , 95, 1258-64	8.7	29
106	Nodal stage migration and prognosis in anal cancer: a systematic review, meta-regression, and simulation study. <i>Lancet Oncology, The</i> , 2017 , 18, 1348-1359	21.7	28
105	Gender and age influence the relationship between serum GH and IGF-I in patients with acromegaly. <i>Clinical Endocrinology</i> , 2002 , 57, 59-64	3.4	27
104	Association of Coloproctology of Great Britain & Ireland (ACPGBI): Guidelines for the Management of Cancer of the Colon, Rectum and Anus (2017) - Multidisciplinary Management. <i>Colorectal Disease</i> , 2017 , 19 Suppl 1, 37-66	2.1	26
103	Association of Coloproctology of Great Britain & Ireland (ACPGBI): Guidelines for the Management of Cancer of the Colon, Rectum and Anus (2017) - Anal Cancer. <i>Colorectal Disease</i> , 2017 , 19 Suppl 1, 82-97.1	27.1	26
102	Determination of IGF-I, IGF-II, IGFBP-2, and IGFBP-3 levels in serum and plasma: comparisons using the Bland-Altman method. <i>Growth Hormone and IGF Research</i> , 2003 , 13, 341-6	2	26

101	Risk-reducing laparoscopic cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for low-grade appendiceal mucinous neoplasm: early outcomes and technique. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2014 , 28, 341-5	5.2	25
100	Screening colonoscopy for acromegaly in perspective. <i>Clinical Endocrinology</i> , 2001 , 55, 731-3	3.4	25
99	Childhood body mass index and height in relation to site-specific risks of colorectal cancers in adult life. <i>European Journal of Epidemiology</i> , 2017 , 32, 1097-1106	12.1	24
98	Multi-level evidence that circulating CK18 is a biomarker of tumour burden in colorectal cancer. <i>British Journal of Cancer</i> , 2012 , 107, 1518-24	8.7	24
97	The effect of cigarette smoking use and cessation on serum insulin-like growth factors. <i>British Journal of Cancer</i> , 2004 , 91, 1525-31	8.7	24
96	Clinico-pathological and treatment-related factors influencing survival in parotid cancer		24
95	Insulin analogues and cancer risk: the emergence of second-generation studies. <i>Diabetologia</i> , 2012 , 55, 7-9	10.3	23
94	Quantification of skeletal metastases in castrate-resistant prostate cancer predicts progression-free and overall survival. <i>BJU International</i> , 2014 , 114, E70-E73	5.6	23
93	Excess adiposity and gastrointestinal cancer. <i>British Journal of Surgery</i> , 2014 , 101, 1518-31; discussion 1531	5.3	22
92	Height and cancer: consistent links, but mechanisms unclear. <i>Lancet Oncology, The</i> , 2011 , 12, 716-7	21.7	22
91	Treatments and outcomes of peritoneal surface tumors through a centralized national service (United kingdom). <i>Diseases of the Colon and Rectum</i> , 2009 , 52, 1705-14	3.1	21
90	A presurgical window-of-opportunity study of metformin in obesity-driven endometrial cancer. <i>Lancet, The</i> , 2015 , 385 Suppl 1, S90	4.0	20
89	Management of local disease relapse. <i>Colorectal Disease</i> , 2011 , 13 Suppl 1, 44-52	2.1	20
88	The effect of hepatic steatosis on survival following resection of colorectal liver metastases in patients without preoperative chemotherapy. <i>Hpb</i> , 2013 , 15, 463-72	3.8	19
87	Determination of large bowel length and loop complexity in patients with acromegaly undergoing screening colonoscopy. <i>Clinical Endocrinology</i> , 2005 , 62, 323-30	3.4	19
86	Obesity and Cancer Treatment Outcomes: Interpreting the Complex Evidence. <i>Clinical Oncology</i> , 2020 , 32, 591-608	2.8	17
85	Current treatment of anal squamous cell carcinoma. <i>Hematology/Oncology Clinics of North America</i> , 2012 , 26, 1315-50	3.1	17
84	Top ten research priorities for detecting cancer early. <i>Lancet Public Health, The</i> , 2019 , 4, e551	22.4	16

83	Obesity as an Avoidable Cause of Cancer (Attributable Risks). <i>Recent Results in Cancer Research</i> , 2016 , 208, 243-256	1.5	16
82	Re: body mass index and risk of lung cancer among never, former, and current smokers. <i>Journal of the National Cancer Institute</i> , 2012 , 104, 1680-1; author reply 1681	9.7	15
81	Obesity paradox and mortality in adults with and without incident type 2 diabetes: a matched population-level cohort study. <i>BMJ Open Diabetes Research and Care</i> , 2017 , 5, e000369	4.5	14
80	Equivalent survival in patients with and without steatosis undergoing resection for colorectal liver metastases following pre-operative chemotherapy. <i>European Journal of Surgical Oncology</i> , 2014 , 40, 1436-44	3.6	14
79	Core outcome research measures in anal cancer (CORMAC): protocol for systematic review, qualitative interviews and Delphi survey to develop a core outcome set in anal cancer. <i>BMJ Open</i> , 2017 , 7, e018726	3	13
78	Anal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2021 , 32, 1087-1100	10.3	13
77	A framework for the in vitro evaluation of cancer-relevant molecular characteristics and mitogenic potency of insulin analogues. <i>Carcinogenesis</i> , 2015 , 36, 1040-50	4.6	12
76	Initial management through the anal cancer multidisciplinary team meeting. <i>Colorectal Disease</i> , 2011 , 13 Suppl 1, 21-8	2.1	12
75	Is "watch-and-wait" after chemoradiotherapy safe in patients with rectal cancer?. <i>BMJ, The</i> , 2018 , 363, k4472	5.9	12
74	Systematic review of outcome measures following chemoradiotherapy for the treatment of anal cancer (CORMAC). <i>Colorectal Disease</i> , 2018 , 20, 371-382	2.1	11
73	Obesity and endometrial cancer: unanswered epidemiological questions. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2016 , 123, 175-8	3.7	11
72	Body composition and outcome in patients undergoing resection of colorectal liver metastases (Br J Surg 2012; 99: 550-557). <i>British Journal of Surgery</i> , 2012 , 99, 1021-2; author reply 1022	5.3	11
71	The long road towards cancer prevention: 4 steps backward and 8 forward. <i>European Journal of Cancer</i> , 2010 , 46, 2660-2	7.5	11
70	Reciprocal relationship between expression of hypoxia inducible factor 1alpha (HIF-1alpha) and the pro-apoptotic protein bid in ex vivo colorectal cancer. <i>British Journal of Cancer</i> , 2008 , 99, 459-63	8.7	11
69	Colorectal neoplasia in acromegaly: the reported increased prevalence is overestimated. <i>Gut</i> , 2000 , 46, 440-1	19.2	11
68	Excess Weight as a Risk Factor Common to Many Cancer Sites: Words of Caution when Interpreting Meta-analytic Evidence. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2017 , 26, 663-665	4	10
67	Chronic insulin exposure does not cause insulin resistance but is associated with chemo-resistance in colon cancer cells. <i>Hormone and Metabolic Research</i> , 2014 , 46, 85-93	3.1	10
66	International consensus recommendations on key outcome measures for organ preservation after (chemo)radiotherapy in patients with rectal cancer. <i>Nature Reviews Clinical Oncology</i> , 2021 , 18, 805-816	19.4	10

65	Systematic reviews and meta-analyses in coloproctology: interpretation and potential pitfalls. <i>Colorectal Disease</i> , 2008 , 10, 21-32	2.1	9
64	Paradoxical elevations in serum IGF-II and IGF binding protein-2 in acromegaly: insights into the regulation of these peptides. <i>Clinical Endocrinology</i> , 2001 , 55, 469-75	3.4	9
63	Change in weight status from childhood to early adulthood and late adulthood risk of colon cancer in men: a population-based cohort study. <i>International Journal of Obesity</i> , 2018 , 42, 1797-1803	5.5	9
62	The Role of High Frequency Dynamic Threshold (HiDT) Serum Carcinoembryonic Antigen (CEA) Measurements in Colorectal Cancer Surveillance: A (Revisited) Hypothesis Paper. <i>Cancers</i> , 2011 , 3, 2302-15	6.6	8
61	Acromegaly and Colorectal Cancer: Risk Assessment Should Be Based on Population-Based Studies. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2002 , 87, 1909-1909	5.6	8
60	Digital histology quantification of intra-hepatic fat in patients undergoing liver resection. <i>European Journal of Surgical Oncology</i> , 2015 , 41, 1020-7	3.6	7
59	Young adulthood body mass index, adult weight gain and breast cancer risk: the PROCAS Study (United Kingdom). <i>British Journal of Cancer</i> , 2020 , 122, 1552-1561	8.7	7
58	Re: Prediagnosis body mass index, physical activity, and mortality in endometrial cancer patients. <i>Journal of the National Cancer Institute</i> , 2014 , 106, djt375	9.7	7
57	The Obesity paradox and survival after colorectal cancer: true or false?. <i>Cancer Causes and Control</i> , 2014 , 25, 1419-22	2.8	7
56	The development of composite circulating biomarker models for use in anticancer drug clinical development. <i>International Journal of Cancer</i> , 2011 , 128, 1843-51	7.5	7
55	Body fatness and bevacizumab-based therapy in metastatic colorectal cancer. <i>Gut</i> , 2010 , 59, 289-90	19.2	7
54	Foreword: Implementing cancer prevention in Europe. <i>European Journal of Cancer</i> , 2010 , 46, 2523-4	7.5	7
53	Incremental benefits of screening colonoscopy over sigmoidoscopy in average-risk populations: a model-driven analysis. <i>Cancer Causes and Control</i> , 2015 , 26, 859-70	2.8	6
52	Prognostic relevance and performance characteristics of serum IGFBP-2 and PAPP-A in women with breast cancer: a long-term Danish cohort study. <i>Cancer Medicine</i> , 2018 , 7, 2391-2404	4.8	6
51	Techniques and Outcome of Surgery for Locally Advanced and Local Recurrent Rectal Cancer. <i>Clinical Oncology</i> , 2016 , 28, 103-115	2.8	6
50	Surveillance after colorectal cancer resection. <i>Lancet, The</i> , 2000 , 355, 1095-6	4.0	6
49	Re: Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGF-binding protein-3. <i>Journal of the National Cancer Institute</i> , 1999 , 91, 2051-2	9.7	6
48	Early stage anal margin cancer: towards evidence-based management. <i>Colorectal Disease</i> , 2019 , 21, 387-391	3.91	5

47	Development of MR quantified pancreatic fat deposition as a cancer risk biomarker. <i>Pancreatology</i> , 2018 , 18, 429-437	3.8	5
46	The effects of sex steroid replacement therapy on an expanded panel of IGF-related peptides. <i>Growth Hormone and IGF Research</i> , 2007 , 17, 210-9	2	5
45	Guidelines for colonoscopic screening in acromegaly are inconsistent with those for other high risk groups. <i>Gut</i> , 2003 , 52, 1071-2; author reply 1072	19.2	5
44	Watch-and-wait versus surgical resection for patients with rectal cancer - AuthorsPreply. <i>Lancet Oncology, The</i> , 2016 , 17, e134-e135	21.7	5
43	Cancer survivorship, excess body fatness and weight-loss intervention-where are we in 2020?. <i>British Journal of Cancer</i> , 2021 , 124, 1057-1065	8.7	5
42	Interaction between co-morbidities and cancer survival. <i>European Journal of Epidemiology</i> , 2019 , 34, 1103-1105	21.054	4
41	Awareness of the link between obesity and cancer in UK school curricula. <i>Lancet, The</i> , 2019 , 393, 1591-1592	11.4	4
40	Limitations of the National Cancer Data Base to Evaluate Early-Stage Anal Cancer Treatment Outcomes. <i>JAMA Surgery</i> , 2018 , 153, 691	5.4	4
39	Comment on Bordeleau et al. The association of basal insulin glargine and/or n-3 fatty acids with incident cancers in patients with dysglycemia. <i>Diabetes Care</i> 2014;37:1360-1366. <i>Diabetes Care</i> , 2014 , 37, e221-2	14.6	4
38	FDG PET-CT imaging for pre operative staging in patients with colorectal cancer. <i>The Cochrane Library</i> , 2012 ,	5.2	4
37	Obesity and cancer in Asia-Pacific populations. <i>Lancet Oncology, The</i> , 2010 , 11, 704-5	21.7	4
36	Insulin-like growth factor-binding protein-3, breast cancer risk, and different serum assays. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2005 , 14, 1844	4	4
35	Temporal improvements in loco-regional failure and survival in patients with anal cancer treated with chemo-radiotherapy: treatment cohort study (1990-2014). <i>British Journal of Cancer</i> , 2020 , 122, 749-758	8.7	3
34	Body-mass index and metastatic melanoma outcomes. <i>Lancet Oncology, The</i> , 2018 , 19, e225	21.7	3
33	Referral pathways and outcome of patients with colorectal peritoneal metastasis (CRPM). <i>European Journal of Surgical Oncology</i> , 2019 , 45, 2310-2315	3.6	3
32	Utility of 18-fluorodeoxyglucose positron emission/computed tomography in the management of recurrent colorectal cancer. <i>ANZ Journal of Surgery</i> , 2012 , 82, 729-36	1	3
31	Comment on: Morden et al. Further exploration of the relationship between insulin glargine and incident cancer: a retrospective cohort study of older Medicare patients. <i>Diabetes Care</i> 2011;34:1965-1971. <i>Diabetes Care</i> , 2012 , 35, e15; author reply e16	14.6	3
30	Cumulative incidence of metachronous colorectal cancer risk for mismatch repair gene mutation carriers is overestimated. <i>Gut</i> , 2012 , 61, 783; author reply 783-4	19.2	3

29	Linkage of the UK Clinical Practice Research Datalink with the national cancer registry. <i>European Journal of Epidemiology</i> , 2019 , 34, 101-102	12.1	3
28	Cancer prevention through weight control-where are we in 2020?. <i>British Journal of Cancer</i> , 2021 , 124, 1049-1056	8.7	3
27	Hormones, Growth Factors, and Tumor Growth32-40		3
26	Watch-and-wait approach for rectal cancer: concepts of a subject-specific method. <i>The Lancet Gastroenterology and Hepatology</i> , 2017 , 2, 627	18.8	2
25	Watch and wait or surgery for clinical complete response in rectal cancer: a need to study both sides. <i>Colorectal Disease</i> , 2020 , 22, 839-840	2.1	2
24	Prospective study of change in liver function and fat in patients with colorectal liver metastases undergoing preoperative chemotherapy: protocol for the CLIFF Study. <i>BMJ Open</i> , 2020 , 10, e027630	3	2
23	Insulin and Cancer: Report of the Proceedings of the First International Workshop, October 27-28, 2007, Döselldorf, Germany. <i>Pediatric Endocrinology Reviews</i> , 2008 , 5, 810-6	1.1	2
22	Clinico-pathological predictors of clinical complete response in rectal cancer.. <i>Cancer Treatment and Research Communications</i> , 2022 , 31, 100540	2	2
21	Anal cancer: different epidemiological and clinical definitions. <i>International Journal of Epidemiology</i> , 2017 , 46, 2091-2092	7.8	1
20	Novel phase I trial design to evaluate the addition of cediranib or selumetinib to preoperative chemoradiotherapy for locally advanced rectal cancer: the DREAMtherapy trial. <i>European Journal of Cancer</i> , 2019 , 117, 48-59	7.5	1
19	Cancer and cardiovascular disease. <i>Lancet, The</i> , 2020 , 395, 1903-1904	40	1
18	Obesity and cancer: links with survival differ from those with incidence. <i>Annals of Oncology</i> , 2015 , 26, 821	10.3	1
17	Colorectal cancer prevention: choosing the most effective population strategy using bio-mathematical approaches. <i>Colorectal Disease</i> , 2007 , 9, 393-6	2.1	1
16	c-MET/VEGFR-2 co-localisation impacts on survival following bevacizumab therapy in epithelial ovarian cancer: an exploratory biomarker study of the phase 3 ICON7 trial.. <i>BMC Medicine</i> , 2022 , 20, 59	11.4	1
15	Growth hormone, the insulin-like growth factor axis, insulin and cancer risk		1
14	Watch-and-wait strategy in rectal cancer - AuthorsPreply. <i>The Lancet Gastroenterology and Hepatology</i> , 2019 , 4, 97	18.8	1
13	Impact of mechanical bowel preparation on survival after colonic cancer resection (Br J Surg 2014: 101: 1594-1600). <i>British Journal of Surgery</i> , 2014 , 101, 1600-1	5.3	0
12	Associations of specific-age and decade recall body mass index trajectories with obesity-related cancer. <i>BMC Cancer</i> , 2021 , 21, 502	4.8	0

11	Indications and outcomes for repeat cytoreductive surgery and heated intra-peritoneal chemotherapy in peritoneal surface malignancy. <i>Surgical Oncology</i> , 2021 , 38, 101572	2.5	o
10	Weight Changes in Type 2 Diabetes and Cancer Risk: A Latent Class Trajectory Model Study.. <i>Obesity Facts</i> , 2021 , 1-10	5.1	o
9	Metformin, Diabetes, and Survival among U.S. Veterans with Colorectal Cancer-Letter. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2017 , 26, 976	4	
8	Cancer surveillance, obesity, and potential bias. <i>Lancet Public Health, The</i> , 2019 , 4, e218	22.4	
7	Obesity and dietary approaches to cancer prevention 2018 , 381-402		
6	The interaction between prognostic and pharmacodynamic biomarkers. <i>British Journal of Cancer</i> , 2013 , 109, 1782-5	8.7	
5	A selective policy in follow-up for bowel cancer. <i>Lancet, The</i> , 1998 , 351, 1891	40	
4	Re: Sternomastoid flap after superficial parotidectomy. <i>British Journal of Oral and Maxillofacial Surgery</i> , 2003 , 41, 281	1.4	
3	Physical Activity Before and After Diagnosis of Colorectal Cancer 2010 , 153-172		
2	Obesity and Cancer369-384		
1	Three-dimensional (3D) magnetic resonance volume assessment and loco-regional failure in anal cancer: early evaluation case-control study. <i>BMC Cancer</i> , 2020 , 20, 1165	4.8	